Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ildong Pharmaceutical Co., Ltd. (249420.KS)
Seoul, KR
Ildong Pharmaceutical Co., Ltd., established in 1941 and headquartered in Seoul, South Korea, is a company dedicated to the development, production, and distribution of a wide array of pharmaceutical products. Its extensive portfolio includes various medications such as anti-diarrheal agents, antibiotics, antifungals, antivirals, antihistamines, anticancer drugs, NSAIDs, and pain relievers, along with essential vitamins, minerals, and nutritional supplements. The company also produces treatments for numerous bodily systems, including cardiovascular, central nervous, dental, endocrine, gastrointestinal, respiratory, topical, and urogenital health, as well as those for blood circulation. Beyond pharmaceuticals, Ildong offers raw material drugs, health foods, cosmetics, and specialized medical devices, such as scar treatment products. Their range also extends to unique treatments for conditions like osteoarthritis, wound care, artificial tears, and feminine hygiene products. In addition to its product offerings, the company manages licenses and provides contract manufacturing services. With a global reach, Ildong Pharmaceutical exports its products to approximately 20 countries. Furthermore, the company has entered into a strategic collaboration with Evotec SE, leveraging Evotec's INDiGO platform to accelerate the development of its proprietary projects.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.68% | -7.29% | -21.79% | -38.37% | -23.93% | -42.51% | +92.31% | +11.53% | +41.27% | +16.86% | +16.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-7.8% Q1'26: +4.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+672.5% ★ Q1'26: +610.4% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-3.8% Q1'26: +10.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+3.1% Q1'26: +6.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.0% Q1'26: +9.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+7.5% Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.77× Q1'26: 4.07× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
460.65B
est: 468.47B (-1.7%)
|
503.91B
est: 502.50B (+0.3%)
|
517.47B
est: 527.00B (-1.8%)
|
561.85B
est: 535.90B (+4.8%)
|
560.13B
est: 552.10B (+1.5%)
|
637.71B
est: 645.00B (-1.1%)
|
600.76B
est: 596.00B (+0.8%)
|
614.94B
est: 640.05B (-3.9%)
|
566.93B
est: 560.20B (+1.2%)
|
557.00B
557.00B – 557.00B
-0.6% YoY
|
678.20B
678.20B – 678.20B
+21.8% YoY
|
| EBITDA |
43.81B
est: -27.88B (+257.1%)
|
50.75B
est: -29.90B (+269.7%)
|
10.51B
est: -31.36B (+133.5%)
|
22.61B
est: -31.89B (+170.9%)
|
-101.34B
est: -32.85B (-208.4%)
|
-80.49B
est: -38.38B (-109.7%)
|
-51.23B
est: -35.47B (-44.4%)
|
33.59B
est: 210.91B (-84.1%)
|
39.90B
est: 184.60B (-78.4%)
|
183.54B
183.54B – 183.54B
-0.6% YoY
|
223.48B
223.48B – 223.48B
+21.8% YoY
|
| EBIT |
24.17B
est: -50.10B (+148.2%)
|
20.03B
est: -53.74B (+137.3%)
|
-17.41B
est: -56.36B (+69.1%)
|
-5.05B
est: -57.31B (+91.2%)
|
-130.65B
est: -59.05B (-121.3%)
|
-110.04B
est: -68.98B (-59.5%)
|
-79.55B
est: -63.74B (-24.8%)
|
7.65B
est: 192.41B (-96.0%)
|
17.32B
est: 168.41B (-89.7%)
|
167.45B
167.45B – 167.45B
-0.6% YoY
|
203.88B
203.88B – 203.88B
+21.8% YoY
|
| Net Income |
19.84B
est: 26.16B (-24.1%)
|
12.72B
est: 21.06B (-39.6%)
|
-13.44B
est: 7.85B (-271.3%)
|
-13.02B
est: 13.44B (-196.9%)
|
-99.71B
est: -22.51B (-342.9%)
|
-142.17B
est: -123.54B (-15.1%)
|
-78.93B
est: -93.24B (+15.3%)
|
-4.58B
est: 39.44B (-111.6%)
|
27.66B
est: 48.45B (-42.9%)
|
20.27B
20.27B – 20.27B
-58.2% YoY
|
43.97B
43.97B – 43.97B
+116.9% YoY
|
| SGA |
90.94B
est: 88.98B (+2.2%)
|
97.23B
est: 95.44B (+1.9%)
|
102.86B
est: 100.09B (+2.8%)
|
96.53B
est: 101.78B (-5.2%)
|
95.38B
est: 104.86B (-9.0%)
|
106.99B
est: 122.50B (-12.7%)
|
82.32B
est: 113.20B (-27.3%)
|
92.79B
est: 98.45B (-5.8%)
|
81.16B
est: 86.17B (-5.8%)
|
85.68B
85.68B – 85.68B
-0.6% YoY
|
104.32B
104.32B – 104.32B
+21.8% YoY
|
| EPS |
876.19
est: 936.49 (-6.4%)
|
534.63
est: 753.97 (-29.1%)
|
-565.08
est: 280.95 (-301.1%)
|
-547.34
est: 481.00 (-213.8%)
|
-4,191.88
est: -806.00 (-420.1%)
|
-5,396.73
est: -4,423.00 (-22.0%)
|
-2,920.01
est: -3,338.00 (+12.5%)
|
-163.63
est: 1,313.00 (-112.5%)
|
942.08
est: 1,613.00 (-41.6%)
|
675.00
675.00 – 675.00
-58.2% YoY
|
1,464.00
1,464.00 – 1,464.00
+116.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Biotech 244580.KS | 1.85% | 2.65M | 0.45% |
| 2 | Samsung KODEX Momentum PLUS ETF 244620.KS | 0.87% | 92.7K | 0.30% |
| 3 | Kodex Healthcare 266420.KS | 0.48% | 216.1K | 0.09% |
| 4 | Kodex KOSPI 226490.KS | 0.03% | 203.3K | 0.15% |
| 5 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.02% | 14.3K | 0.74% |
| 6 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.01% | 40.7K | 0.74% |
| 7 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.01% | 57.1K | 0.55% |
| 8 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 442.8K | 0.06% |
| 9 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.03M | 0.06% |
| 10 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 116.2K | 0.46% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yun Paul Woongsup | CEO & Chairman | 867M | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 249420.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
